All Stories

  1. A Small Molecule Antagonist of CX3CR1 (KAND567) Inhibited the Tumor Growth-Promoting Effect of Monocytes in Chronic Lymphocytic Leukemia (CLL)

    Article • Cancers, November 2024, MDPI AG

    Dr Mohammad Hojjat-farsangi

  2. A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells

    Article • Pharmaceutics, April 2023, MDPI AG

    Dr Mohammad Hojjat-farsangi

  3. The prognostic and therapeutic potential of HO-1 in leukemia and MDS

    Article • Cell Communication and Signaling, March 2023, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  4. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies

    Article • Expert Opinion on Therapeutic Targets, December 2022, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  5. Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model

    Article • International Immunopharmacology, December 2022, Elsevier

    Dr Mohammad Hojjat-farsangi

  6. Cloning, expression and characterization of a peptibody to deplete myeloid derived suppressor cells in a murine mammary carcinoma model

    Article • Protein Expression and Purification, December 2022, Elsevier

    Dr Mohammad Hojjat-farsangi

  7. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions

    Article • Expert Opinion on Therapeutic Targets, November 2022, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  8. Combined inhibition of EZH2 and CD73 molecules by folic acid-conjugated SPION-TMC nanocarriers loaded with siRNA molecules prevents TNBC progression and restores anti-tumor responses

    Article • Life Sciences, November 2022, Elsevier

    Dr Mohammad Hojjat-farsangi

  9. Increased susceptibility to doxorubicin-induced cell death in acute lymphocytic leukemia cells by inhibiting serine/threonine WEE1 kinase expression using the chitosan-carboxymethyl dextran-polyethylene glycol-TAT nanoparticles

    Article • Journal of Drug Delivery Science and Technology, November 2022, Elsevier

    Dr Mohammad Hojjat-farsangi

  10. A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

    Article • Pharmaceutics, October 2022, MDPI AG

    Dr Mohammad Hojjat-farsangi

  11. Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women

    Article • Reproductive Sciences, September 2022, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  12. Evaluation of CD39, CD73, HIF-1α, and their related miRNAs expression in decidua of preeclampsia cases compared to healthy pregnant women

    Article • Molecular Biology Reports, September 2022, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  13. Expression level of immune checkpoint inhibitory factors in preeclampsia

    Article • Human Immunology, August 2022, Elsevier

    Dr Mohammad Hojjat-farsangi

  14. The molecular biology and therapeutic potential of Nrf2 in leukemia

    Article • Cancer Cell International, July 2022, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  15. The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia

    Article • IUBMB Life, July 2022, Wiley

    Dr Mohammad Hojjat-farsangi

  16. RETRACTED ARTICLE: Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model

    Article • Pharmaceutical Research, June 2022, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  17. Early stage evaluation of colon cancer using tungsten disulfide quantum dots and bacteriophage nano-biocomposite as an efficient electrochemical platform

    Article • Cancer Nanotechnology, March 2022, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  18. RETRACTED: Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models

    Article • Life Sciences, January 2022, Elsevier

    Dr Mohammad Hojjat-farsangi

  19. Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection

    Article • Viral Immunology, October 2021, Mary Ann Liebert Inc

    Dr Mohammad Hojjat-farsangi

  20. RETRACTED: Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo

    Article • International Journal of Biological Macromolecules, September 2021, Elsevier

    Dr Mohammad Hojjat-farsangi

  21. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung

    Article • Cell Death and Disease, June 2021, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  22. Silencing STAT3 enhances sensitivity of cancer cells to doxorubicin and inhibits tumor progression

    Article • Life Sciences, June 2021, Elsevier

    Dr Mohammad Hojjat-farsangi

  23. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

    Article • eJHaem, May 2021, Wiley

    Dr Mohammad Hojjat-farsangi

  24. Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy

    Article • Cytokine, May 2021, Elsevier

    Dr Mohammad Hojjat-farsangi

  25. TIGIT and CD155 as Immune-Modulator Receptor and Ligand on CD4+T cells in Preeclampsia Patients

    Article • Immunological Investigations, April 2021, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  26. T‐cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer

    Article • IUBMB Life, March 2021, Wiley

    Dr Mohammad Hojjat-farsangi

  27. Application of Emerging Plant-Derived Nanoparticles as a Novel Approach for Nano-Drug Delivery Systems

    Article • Immunological Investigations, February 2021, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  28. Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules

    Article • January 2021, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  29. EP4 receptor as a novel promising therapeutic target in colon cancer

    Article • Pathology - Research and Practice, December 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  30. Oncostatin M: A mysterious cytokine in cancers

    Article • International Immunopharmacology, November 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  31. Immunoreactivity pattern of monoclonal antibodies against Hepatitis B vaccine with global Hepatitis B virus genotypes

    Article • Clinica Chimica Acta, November 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  32. RETRACTED: Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression

    Article • Life Sciences, November 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  33. Intrauterine administration of autologous hCG- activated peripheral blood mononuclear cells improves pregnancy outcomes in patients with recurrent implantation failure; A double-blind, randomized control trial study

    Article • Journal of Reproductive Immunology, November 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  34. Small-Molecule Inhibitors Targeting Receptor Tyrosine Kinases in Cancer

    Article • October 2020, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  35. IL-10-producing B cells play important role in the pathogenesis of recurrent pregnancy loss

    Article • International Immunopharmacology, October 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  36. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy

    Article • Nanomedicine Nanotechnology Biology and Medicine, October 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  37. Exosome: From leukemia progression to a novel therapeutic approach in leukemia treatment

    Article • BioFactors, August 2020, Wiley

    Dr Mohammad Hojjat-farsangi

  38. Berberine: A novel therapeutic strategy for cancer

    Article • IUBMB Life, July 2020, Wiley

    Dr Mohammad Hojjat-farsangi

  39. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein

    Article • Human Vaccines & Immunotherapeutics, July 2020, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  40. CDK1 in Breast Cancer: Implications for Theranostic Potential

    Article • Anti-Cancer Agents in Medicinal Chemistry, July 2020, Bentham Science Publishers

    Dr Mohammad Hojjat-farsangi, Gholamreza Azizi, Hamed Mohammadi

  41. Tumor associated macrophages in the molecular pathogenesis of ovarian cancer

    Article • International Immunopharmacology, July 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  42. Toxicity of Saffron Extracts on Cancer and Normal Cells: A Review Article

    Article • Asian Pacific Journal of Cancer Prevention, July 2020, EpiSmart Science Vector Ltd

    Dr Mohammad Hojjat-farsangi, Abdolreza Sotoodeh jahromi

  43. ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells

    Article • Biomedicines, June 2020, MDPI AG

    Dr Mohammad Hojjat-farsangi

  44. Concomitant blockade of A2AR and CTLA‐4 by siRNA‐loaded polyethylene glycol‐chitosan‐alginate nanoparticles synergistically enhances antitumor T‐cell responses

    Article • Journal of Cellular Physiology, June 2020, Wiley

    Dr Mohammad Hojjat-farsangi

  45. Nanomedicine for improvement of dendritic cell-based cancer immunotherapy

    Article • International Immunopharmacology, June 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  46. Cancer associated fibroblasts as novel promising therapeutic targets in breast cancer

    Article • Pathology - Research and Practice, May 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  47. Silencing of IL-6 and STAT3 by siRNA loaded hyaluronate-N,N,N-trimethyl chitosan nanoparticles potently reduces cancer cell progression

    Article • International Journal of Biological Macromolecules, April 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  48. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer

    Article • Life Sciences, April 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  49. Identification of genes and miRNAs associated with angiogenesis, metastasis, and apoptosis in colorectal cancer

    Article • Gene Reports, March 2020, Elsevier

    Dr Mohammad Hojjat-farsangi

  50. The Association between Inflammatory Cytokines and miRNAs with Slow Coronary Flow Phenomenon

    Article • Iranian Journal of Allergy Asthma and Immunology, February 2020, Knowledge E

    Dr Mohammad Hojjat-farsangi

  51. E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions

    Article • Clinica Chimica Acta, November 2019, Elsevier

    Dr Mohammad Hojjat-farsangi

  52. Blockage of immune checkpoint molecules increases T‐cell priming potential of dendritic cell vaccine

    Article • Immunology, October 2019, Wiley

    Dr Mohammad Hojjat-farsangi

  53. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer

    Article • Prostaglandins & Other Lipid Mediators, October 2019, Elsevier

    Dr Mohammad Hojjat-farsangi

  54. Oxidative stress, inflammatory settings, and microRNA regulation in the recurrent implantation failure patients with metabolic syndrome

    Article • American Journal of Reproductive Immunology, August 2019, Wiley

    Dr Mohammad Hojjat-farsangi

  55. Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway

    Article • International Journal of Biological Macromolecules, July 2019, Elsevier

    Dr Mohammad Hojjat-farsangi

  56. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy

    Article • Molecular Diagnosis & Therapy, May 2019, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  57. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior

    Article • The American Journal of Surgical Pathology, March 2019, Wolters Kluwer Health

    Dr Mohammad Hojjat-farsangi

  58. Metabolic syndrome mediates proinflammatory responses of inflammatory cells in preeclampsia

    Article • American Journal of Reproductive Immunology, February 2019, Wiley

    Dr Mohammad Hojjat-farsangi

  59. CD73 as a potential opportunity for cancer immunotherapy

    Article • Expert Opinion on Therapeutic Targets, December 2018, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  60. Promising immunotherapy: Highlighting cytokine‐induced killer cells

    Article • Journal of Cellular Biochemistry, December 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  61. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis

    Article • Journal of Cellular Physiology, December 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  62. Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer

    Article • Journal of Cellular Biochemistry, December 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  63. Polymorphism of Foxp3 gene affects the frequency of regulatory T cells and disease activity in patients with rheumatoid arthritis in Iranian population

    Article • Immunology Letters, December 2018, Elsevier

    Dr Mohammad Hojjat-farsangi

  64. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer

    Article • Biomedicine & Pharmacotherapy, December 2018, Elsevier

    Dr Mohammad Hojjat-farsangi

  65. The role of DEAD-box RNA helicase p68 (DDX5) in the development and treatment of breast cancer

    Article • Journal of Cellular Physiology, November 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  66. The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia

    Article • Journal of Cellular Physiology, October 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  67. Altered T-cell subpopulations in recurrent pregnancy loss patients with cellular immune abnormalities

    Article • Journal of Cellular Physiology, September 2018, Wiley

    Dr Mohammad Hojjat-farsangi

  68. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib

    Article • PLOS One, June 2018, PLOS

    Dr Mohammad Hojjat-farsangi

  69. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice

    Article • Journal of Cellular Physiology, May 2018, Wiley

    Gholamreza Azizi, Fatemeh Atyabi, Dr Mohammad Hojjat-farsangi

  70. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells

    Article • Leukemia, March 2018, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  71. Kisspeptin serum levels in acute myocardial infarction patients and healthy individuals

    Article • Biomedical Research and Therapy, March 2018, Biomedical Research and Therapy

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  72. Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells

    Article • PLOS One, February 2018, PLOS

    Dr Mohammad Hojjat-farsangi

  73. Nanoparticles in cancer therapy

    Article • Immunology Letters, October 2017, Elsevier

    Hamed Mohammadi, Dr Mohammad Hojjat-farsangi

  74. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg)

    Article • Antiviral Research, August 2017, Elsevier

    Dr Mohammad Hojjat-farsangi

  75. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer

    Article • Journal of Cellular Physiology, May 2017, Wiley

    Hamed Mohammadi, Dr Mohammad Hojjat-farsangi

  76. Recent advances in targeting mTOR signaling pathway using small molecule inhibitors

    Article • Journal of Drug Targeting, October 2016, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  77. First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor

    Article • Annals of Oncology, October 2016, Elsevier

    Dr Mohammad Hojjat-farsangi

  78. Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy

    Article • Current Drug Targets, September 2016, Bentham Science Publishers

    Dr Mohammad Hojjat-farsangi

  79. Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis

    Article • Journal of Immunotoxicology, July 2016, Taylor & Francis

    Mousa Mohammadnia-Afrouzi, Dr Mohammad Hojjat-farsangi

  80. Mechanisms of tumor cell resistance to the current targeted-therapy agents

    Article • Tumor Biology, May 2016, Springer Science + Business Media

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  81. Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia

    Article • Tumor Biology, April 2016, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  82. Sero-Epidemiological Study of Hepatitis E Virus among Thalassemia as High Risk Patients: A Cross-Sectional Survey in Jahrom, Southern, Iran

    Article • Global Journal of Health Science, February 2016, Canadian Center of Science and Education

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  83. Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia

    Article • PLOS One, November 2015, PLOS

    Dr Mohammad Hojjat-farsangi

  84. Association of Tumor Growth Factor-β and Interferon-γ Serum Levels With Insulin Resistance in Normal Pregnancy

    Article • Global Journal of Health Science, September 2015, Canadian Center of Science and Education

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  85. Lack of Association Between rs17568 Polymorphism in OX40 Gene and Myocardial Infarction, Southern of Iran

    Article • Global Journal of Health Science, September 2015, Canadian Center of Science and Education

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  86. Ibrutinib-A double-edge sword in cancer and autoimmune disorders

    Article • Journal of Drug Targeting, September 2015, Taylor & Francis

    Abdolreza Sotoodeh jahromi , Dr Mohammad Hojjat-farsangi

  87. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

    Article • Journal of Drug Targeting, July 2015, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  88. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy

    Article • Tumor Biology, July 2015, Springer Science + Business Media

    Mousa Mohammadnia-Afrouzi, Dr Mohammad Hojjat-farsangi

  89. The skewed balance between Tregs and Th17 in chronic lymphocytic leukemia

    Article • Future Oncology, May 2015, Future Medicine

    Dr Mohammad Hojjat-farsangi

  90. Novel and emerging targeted-based cancer therapy agents and methods

    Article • Tumor Biology, February 2015, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  91. The receptor tyrosine kinase ROR1 – An oncofetal antigen for targeted cancer therapy

    Article • Seminars in Cancer Biology, December 2014, Elsevier

    Dr Mohammad Hojjat-farsangi

  92. The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

    Article • British Journal of Haematology, November 2014, Wiley

    Dr Mohammad Hojjat-farsangi

  93. Ligation of human Fc receptor like-2 by monoclonal antibodies down-regulates B-cell receptor-mediated signalling

    Article • Immunology, October 2014, Wiley

    Dr Mohammad Hojjat-farsangi

  94. Abstract 4770: Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr Mohammad Hojjat-farsangi

  95. Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

    Article • International Journal of Molecular Sciences, August 2014, MDPI AG

    Dr Mohammad Hojjat-farsangi

  96. Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia

    Article • Human Immunology, February 2014, Elsevier

    Dr Mohammad Hojjat-farsangi

  97. The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells

    Article • PLOS One, October 2013, PLOS

    Dr Mohammad Hojjat-farsangi

  98. Construction and characterization of a new chimeric antibody against HER2

    Article • Immunotherapy, July 2013, Future Medicine

    Dr Mohammad Hojjat-farsangi

  99. Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia

    Article • Experimental Hematology, July 2013, Elsevier

    Dr Mohammad Hojjat-farsangi

  100. Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia

    Article • Cytokine, June 2013, Elsevier

    Dr Mohammad Hojjat-farsangi

  101. Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma Cells

    Article • PLOS One, April 2013, PLOS

    Dr Mohammad Hojjat-farsangi

  102. Increased Frequency of CD8+and CD4+Regulatory T Cells in Chronic Lymphocytic Leukemia: Association with Disease Progression

    Article • Cancer Investigation, January 2013, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  103. Construction and characterization of a new chimeric antibody against HER2

    Article • Frontiers in Immunology, January 2013, Frontiers

    Dr Mohammad Hojjat-farsangi

  104. Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia

    Article • Blood, November 2012, American Society of Hematology

    Dr Mohammad Hojjat-farsangi

  105. Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

    Article • Leukemia & Lymphoma, October 2012, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  106. 162 Investigation of TLR7/8 and 9 Agonists and CD40-ligand Costimulation on EBV Transformation of B Cells of Chronic Lymphocytic Leukemia

    Article • European Journal of Cancer, July 2012, Elsevier

    Dr Mohammad Hojjat-farsangi

  107. T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile

    Article • Medical Oncology, June 2012, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  108. Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

    Article • Journal of Clinical Immunology, March 2012, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  109. Cernunnos influences human immunoglobulin class switch recombination and may be associated with B cell lymphomagenesis

    Article • Journal of Experimental Medicine, February 2012, Rockefeller University Press

    Dr Mohammad Hojjat-farsangi

  110. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

    Article • Leukemia, January 2012, Springer Science + Business Media

    Dr Mohammad Hojjat-farsangi

  111. ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) - a Survival Factor for CLL Cells

    Article • Blood, November 2011, American Society of Hematology

    Dr Mohammad Hojjat-farsangi

  112. 1.7 Telomere Length and Expression of Human Telomerase Reverse Transcriptase Splice Variants in Chronic Lymphocytic Leukemia

    Article • Clinical Lymphoma Myeloma & Leukemia, October 2011, Elsevier

    Dr Mohammad Hojjat-farsangi

  113. 9209 POSTER Unbalanced Frequency of Regulatory T Cells in Different Subsets of Chronic Lymphocytic Leukemia

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Mohammad Hojjat-farsangi

  114. Ror1 Targeting Monoclonal Antibodies Induced Apoptosis of Chronic Lymphocytic Leukemia Cells– A Potential Novel Therapeutic Approach

    Article • Blood, November 2010, American Society of Hematology

    Dr Mohammad Hojjat-farsangi

  115. Expression Profile of Galectin-1 and Galectin-3 Molecules in Different Subtypes of Chronic Lymphocytic Leukemia

    Article • Cancer Investigation, June 2010, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  116. Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia

    Article • Cancer Science, December 2009, Wiley

    Dr Mohammad Hojjat-farsangi

  117. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, October 2009, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  118. Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia

    Article • International Journal of Cancer, November 2008, Wiley

    Dr Mohammad Hojjat-farsangi

  119. Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia

    Article • Human Immunology, October 2008, Elsevier

    Dr Mohammad Hojjat-farsangi

  120. Analysis of the immunoglobulin heavy chain variable region gene expression in Iranian patients with chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Mohammad Hojjat-farsangi

  121. Assessment of the immune system in 55 Iranian patients with vitiligo

    Article • Journal of the European Academy of Dermatology and Venereology, November 2005, Wiley

    Dr Mohammad Hojjat-farsangi